# US 2014/0193383 A1 · Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193383 A1 - Document ID: US20140193383A1 - Status: Published application - Kind: A1 - Application number: 13/971,884 - Filed: 2013-08-21 - Published: 2014-07-10 - Earliest claimed: 2005-02-11 - Assignees: Technologies Biolactis Inc. - Applicants: Technologies Biolactis Inc. - Inventors: Pierre Lemieux; Louis Phillippe Precourt; Eric Simard - Web page: https://patentgrep.com/patent/US20140193383A1 ## CPC - A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis - A23C 9/1234: {characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.} - A23C 21/026: {containing, or treated only with, lactic acid producing bacteria, bifidobacteria or propionic acid bacteria} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61P 1/12: Antidiarrhoeals - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/06: Antihyperlipidemics - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 9/12: Antihypertensives - A61P 17/06: Antipsoriatics - A61P 19/00: Drugs for skeletal disorders - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/04: Antibacterial agents - A61P 35/00: Antineoplastic agents - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/02: Immunomodulators - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract In accordance with the present invention, there is provided a probiotic composition comprising an effective amount of Lactobacillus kefiranofaciens in association with a suitable carrier. The probiotic composition has many probiotic effects such as intestinal adherence, intestinal persistence, positive modulation of the intestinal microflora, protection against intestinal pathogens, immunomodulation, protection against systemic inflammation, protection against intestinal inflammation, protection against allergies, protection against diarrhea, protection against diabetes, protection against hyperlipidemia and protection against colon cancer. In accordance with the present invention, there is also provided a method of treatment and/or prevention of a number of diseases for which the composition has a beneficial effect. For example, the composition is useful for fermenting a product which in turn finds utility in the treatment of hypertension, the treatment of weight disorder, the treatment of hyperlipidemia or the treatment of triglyceride disorder. ## Claims ### Claim 1 A probiotic composition comprising an effective amount of Lactobacillus kefiranofaciens in association with a suitable carrier. ### Claim 2 (depends on 1) The composition of claim 1, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 3 (depends on 1) The composition of claim 1, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSP and ES1. ### Claim 4 (depends on 1) The composition of claim 1, having a probiotic effect selected from the group consisting of intestinal adherence, intestinal persistence, positive modulation of the intestinal microflora, protection against intestinal pathogens, immunomodulation, protection against systemic inflammation, protection against intestinal inflammation, protection against allergies, protection against diarrhea, protection against diabetes, protection against hyperlipidemia and protection against colon cancer. ### Claim 5 (depends on 1) The composition of claim 1, wherein said composition is for oral, rectal or vaginal administration. ### Claim 6 A method for providing positive modulation of the intestinal microflora in a subject comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 7 (depends on 6) The method of claim 6, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 8 (depends on 6) The method of claim 6, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 9 A method for protecting a subject against intestinal inflammation comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 10 (depends on 9) The method of claim 9, wherein said intestinal inflammation is caused by an inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC) or by an irritable bowel syndrome (IBS). ### Claim 11 (depends on 9) The method of claim 9, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 12 (depends on 9) The method of claim 9, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 13 A method for protecting a subject against allergies and/or autoimmune diseases comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 14 (depends on 13) The method of claim 13, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 15 (depends on 13) The method of claim 13, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 16 A method for protecting a subject against diarrhea comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 17 (depends on 16) The method of claim 16, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 18 (depends on 16) The method of claim 16, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 19 A method for protecting a subject against diabetes comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 20 (depends on 19) The method of claim 19, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 21 (depends on 19) The method of claim 19, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 22 A method for protecting a subject against hyperlipidemia comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 23 (depends on 22) The method of claim 22, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 24 (depends on 22) The method of claim 22, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 25 A method for protecting a subject against colon cancer comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 26 (depends on 25) The method of claim 25, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 27 (depends on 25) The method of claim 25, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 28 A method for treating and/or preventing intestinal inflammation in a subject comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 29 (depends on 28) The method of claim 28, wherein said intestinal inflammation is caused by an inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC) or by an irritable bowel syndrome (IBS). ### Claim 30 (depends on 28) The method of claim 28, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 31 (depends on 28) The method of claim 28, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 32 A method for treating and/or preventing allergies and/or autoimmune diseases in a subject comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 33 (depends on 32) The method of claim 32, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 34 (depends on 32) The method of claim 32, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 35 A method for treating and/or preventing diarrhea in a subject comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 36 (depends on 35) The method of claim 35, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 37 (depends on 35) The method of claim 35, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 38 A method for treating and/or preventing diabetes in a subject comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 39 (depends on 38) The method of claim 38, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 40 (depends on 38) The method of claim 38, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 41 A method for treating and/or preventing hyperlipidemia in a subject comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 42 (depends on 41) The method of claim 41, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 43 (depends on 41) The method of claim 41, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 44 A method for treating and/or preventing colon cancer in a subject comprising the step of administering to said subject an effective amount of Lactobacillus kefiranofaciens. ### Claim 45 (depends on 44) The method of claim 44, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 46 (depends on 44) The method of claim 44, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 47 Use of Lactobacillus kefiranofaciens as a probiotic compound. ### Claim 48 (depends on 47) The use as claimed in claim 47, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 49 (depends on 47) The use as claimed in claim 47, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, INIX, K2, BioSp and ES1. ### Claim 50 (depends on 47) The use as claimed in claim 47, having a probiotic effect selected from the group consisting of intestinal adherence, intestinal persistence, positive modulation of the intestinal microflora, protection against intestinal pathogens, immunomodulation, protection against systemic inflammation, protection against intestinal inflammation, protection against allergies, protection against diarrhea, protection against diabetes, protection against hyperlipidemia and protection against colon cancer. ### Claim 51 (depends on 47) The use as claimed in claim 47, wherein said Lactobacillus kefiranofaciens is for oral administration. ### Claim 52 (depends on 51) The use as claimed in claim 51, wherein said Lactobacillus kefiranofaciens is administered is a form selected from the group consisting of a live bacterial population, a lyophilized bacterial population, as a fermented dairy product and as a non-viable bacterial sample. ### Claim 53 (depends on 51) The use as claimed in claim 51, wherein said non-viable bacterial sample is selected from the group consisting of a heat-killed bacteria, an irradiated bacteria and a lysed bacteria. ### Claim 54 (depends on 47) The use as claimed in claim 47, wherein the probiotic compound has an anti-inflammatory effect. ### Claim 55 (depends on 54) The use of claim 54 for treating psoriasis. ### Claim 56 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55) The use of any one of claims 47-55, in association with an anti-inflammatory compound. ### Claim 57 (depends on 57) The use of claim 57 wherein the anti-inflammatory compound is 5-ASA or a corticosteroid. ### Claim 58 (depends on 47) The used of claim 47, for the manufacture of a medicament for treating psoriasis. ### Claim 59 Use of Lactobacillus kefiranofaciens to ferment whey. ### Claim 60 (depends on 60) The use as claimed in claim 60, wherein said whey is cheese whey. ### Claim 61 (depends on 60, 61) The use as claimed in any one of claims 60 and 61, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 62 (depends on 60, 61) The use as claimed in any one of claims 60 and 61, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, IN IX, K2, BioSp and ES1. ### Claim 63 Use of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens for the treatment of a cardiovascular disease. ### Claim 64 Use of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens for the treatment of hypertension. ### Claim 65 Use of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens for the treatment of weight disorder. ### Claim 66 Use a of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens for the treatment of hyperlipidemia ### Claim 67 Use a of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens for the treatment of triglyceride disorder. ### Claim 68 (depends on 64, 65, 66, 67, 68) The use as claimed in anyone of claim 64-68, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 69 (depends on 64, 65, 66, 67, 68) The use as claimed in anyone of claim 64-68, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, IN IX, K2, BioSp and ES1. ### Claim 70 Use of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens in the manufacture of a medicament for the treatment of cardiovascular disease. ### Claim 71 Use of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens in the manufacture of a medicament for the treatment of hypertension. ### Claim 72 Use of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens in the manufacture of a medicament for the treatment of weight disorder. ### Claim 73 Use of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens in the manufacture of a medicament for the treatment of hyperlipidemia. ### Claim 74 of a product obtained from the fermentation of whey by Lactobacillus kefiranofaciens in the manufacture of a medicament for the treatment of triglyceride disorder. ### Claim 75 (depends on 71, 72, 73, 74, 75) The use as claimed in anyone of claims 71-75, wherein said Lactobacillus kefiranofaciens is selected from the group consisting of Lactobacillus kefiranofaciens subsp. kefiranofaciens and Lactobacillus kefiranofaciens subsp. kefirgranum. ### Claim 76 (depends on 71, 72, 73, 74, 75) The use as claimed in anyone of claim 71-75, wherein said Lactobacillus kefiranofaciens is a strain selected from the group consisting of R2C2, IN IX, K2, BioSp and ES1.